We engage in new product opportunities with partners that provide an active ingredient that may be improved by combining it with our drug delivery technologies.

We are using our proprietary drug delivery systems OctoDEX and PolyActive to develop products that provide controlled and prolonged release of a drug, which enables reduced dosing frequency and reduced risk of side effects with comparable or better efficacy relative to immediate release drugs. Rather than seeking to discover novel drug candidates through early stage research activities, we focus on the development of longacting, controlled-release versions of known protein therapeutics and other drugs.

In contrast to certain other approaches to improve the clinical benefit of protein therapeutics, such as chemical modification (including pegylation and polymer conjugates) or protein engineering (including changes in primary structure and fusion), our technologies have the advantage of efficiently and gradually delivering a drug in its native form.